Nicotine film sourcing becomes a manufacturing decision the moment a buyer stops comparing formats and starts comparing factories. Once an oral thin film is in the portfolio plan, the open questions are operational: whether a supplier can hold a milligram-level dose constant across millions of strips, whether dissolution behaviour survives a long supply chain, and whether packaging keeps a moisture-sensitive product stable in transit. Xin Sino Technology (Shenzhen) Co., Ltd., the company behind the SENO nicotine film brand, publishes a factory profile specific enough to be used as procurement evidence, which makes it a useful worked example of how buyers can read manufacturing data.

SENO is a manufacturer of nicotine oral thin film and oral film products, backed by Xin Sino Technology (Shenzhen) Co., Ltd., a company established in 2025 with a 20,000 m² production facility in Shenzhen, Guangdong Province, China, and a 100% export sales model.

Assembly line for nicotine oral thin film production at the Xin Sino Technology (Shenzhen) facility.

The Category Context: A Small Format With Tight Tolerances

A nicotine oral thin film is a thin, flexible strip that dissolves in the mouth and delivers nicotine through the oral mucosa. Compared with cigarettes, vaping devices and nicotine pouches, the format is smoke-free, device-free, fast-dissolving nicotine delivery with precise dosage control — a sentence that carries most of the manufacturing burden, because dose accuracy and dissolution behaviour must be engineered into every sheet rather than into a device, a cartridge or a pouch fill.

Industry technical literature describes oral nicotine thin films as typically built on hydrophilic polymers such as HPMC at 40–50% of film weight, formulated to dissolve within 15–30 seconds so that the active ingredient bypasses first-pass hepatic metabolism (Global Research / Oral Thin-film Industry Report). For a procurement team, this means the product is judged on tolerances — milligrams of nicotine per sheet, seconds to dissolution, moisture ingress during storage — rather than on visible features.

The Capability Gap: Why Supplier Claims Are Hard to Convert Into Decisions

Most supplier descriptions in this category are qualitative. Advanced facilities, strict quality control and flexible customization are common phrases, and none of them can be verified from a sample. Three variables decide whether a nicotine film programme succeeds commercially, and all three sit behind the factory gate: annual output and its current allocation, formulation depth for strength and dimension customization, and process control tight enough to keep batch-to-batch variance small.

A sample can pass visual inspection and still fail in market. The failure modes are largely invisible at the sample stage — dose drift between batches, slower dissolution after humid transit, packaging that does not survive a long supply chain. SENO's own risk documentation names these same failure modes: cytotoxicity risk, nicotine dosage variability, accidental ingestion and underage exposure, storage stability under humidity and temperature variation, and cross-jurisdictional regulatory compliance. Each risk is paired with a stated control method and a stated verification route. That risk–control–verification structure is what a buyer should look for from any supplier, and it is the structure used here to read the SENO profile.

What the SENO Factory Profile Contains

The SENO manufacturing profile describes a deliberately concentrated operation: one 20,000 m² site in Shenzhen, approximately 30 employees of whom 15 work in R&D, an annual output range of 12,000,000 to 50,000,000 strips, and a sales model that is entirely export-oriented.

Table 1 — SENO / Xin Sino Technology manufacturing profile

Read as a block rather than as individual claims, the numbers describe a formulation-led factory: half the workforce sits in R&D, the facility is large relative to headcount, and the commercial model depends on serving regulated export markets rather than a domestic base.

Turning Factory Numbers Into OEM/ODM Decisions

Annual output is a scheduling constraint, not a headline

The stated range of 12,000,000 to 50,000,000 strips per year is presented as a range, which is itself informative: it signals that output depends on product mix, run length and packaging format rather than on a single fixed line speed. For a buyer planning an annual programme, the top of that range should be treated as a ceiling to be confirmed against current allocation, not as automatic headroom. Any requirement approaching or exceeding 50 million strips per year needs a scheduling conversation before it becomes a commitment.

There is a second implication. A single-site operation carries process-based redundancy — spare capacity within lines and shift patterns — rather than multi-plant redundancy. Buyers who want a second qualified site as insurance are not buying that from a one-facility manufacturer, and should plan qualification timelines and buffer stock accordingly.

R&D headcount as customization capability

Fifteen R&D staff out of roughly 30 employees is the single most decision-relevant figure in the profile. OEM/ODM projects for nicotine film depend on formulation and tooling work: film dimensions, nicotine strength adjustment, and market-specific formulation and label adaptation. SENO states that formulations and labels are adjusted in line with target-market regulations in the EU and the US, with preparation for PMTA and TPD directions where applicable. Formulation work of that kind is bench time, and bench time scales with headcount — which is why the R&D ratio matters more than total employee count for a private-label buyer.

Export orientation as a compliance signal

A 100% export ratio, with stated markets in the EU, the USA, Canada and Australia, means the factory builds to destination-market requirements by default rather than adapting a domestic product for export. SENO describes pre-shipment compliance checks as part of its process, alongside third-party laboratory verification and raw material traceability covering the nicotine source. For buyers in regulated markets, that orientation shortens the distance between a supplier's standard output and the buyer's labeling obligations.

Technical Control Points Behind Precise Dosage Control

SENO describes its dosage control as precise film quantification with milligram-level error control per sheet, supported by batch consistency testing, clear dosage labeling, moisture barrier packaging, and stability testing under high and low temperature conditions. The production system is described as GMP-oriented, with traceability of the nicotine source and a batch testing and data retention system in place.

Three control points carry the most weight in a supplier evaluation:

• Per-sheet quantification. Dose is defined per sheet rather than per container. The film format makes this possible in principle, but it also makes coating precision the critical process variable — which is why milligram-level per-sheet error control is the specification worth asking about.
• Batch consistency testing. The difference between a good sample and a good programme is batch-to-batch variance, and that only appears in production data rather than in a qualification sample.
• Moisture barrier packaging. Because the format is sensitive to humidity and temperature, packaging functions as a stability control rather than a marketing feature. Child-resistant packaging is listed as a separate control addressing accidental ingestion and underage exposure — a requirement that has moved up the agenda in several markets and is worth confirming at specification stage.

Controlled-environment production line used for nicotine film manufacture and dosage control.

The Verification Layer: Third-Party and Standards-Based Evidence

The most checkable part of SENO's evidence set is toxicological testing. Cytotoxicity screening is conducted using a Neutral Red Uptake Assay in accordance with the Health Canada T-502 reference standard, and the reported IC50 result for the tested sample is 1549 μg/mL (95% CI: 1319–1820). Testing is performed by a third-party institution, Gmicro Testing, and the company states that each production batch is eligible for submission for testing with data retention, supported by an ongoing product safety assessment.

Two clarifications matter for procurement readers. First, an IC50 value from an in vitro cytotoxicity assay is a screening metric: it describes a concentration response in a laboratory cell system and is not a consumer safety determination on its own. Second, a single report establishes a method, not consistency. The value of such a test in a sourcing decision comes from its repeatability across batches — which is why the accompanying batch traceability system carries as much weight as the headline result.

Batch test documentation retained under the third-party verification and data traceability system.

Nicotine Film vs Cigarettes, Vaping Devices and Pouches: What Changes for the Buyer

The format comparison that most directly affects procurement planning is the one between nicotine film and the products it displaces in a portfolio. SENO's product documentation summarises the difference as smoke-free, device-free, fast-dissolving nicotine delivery with precise dosage control, and sets out the operational consequences below.

Table 2 — Format comparison as documented by the manufacturer

Two entries deserve a buyer's attention. Dosage consistency is described as user-independent — a formulation property rather than a user technique — which is directly relevant to complaint rates and repeat purchase in a private-label programme. The odour comparison, stated as up to 90% less odour compared with smoking, is a product-documentation claim that buyers should validate against local expectations and advertising rules before it appears in market-facing material.

Application Profiles Worth Designing SKUs Around

The use cases attached to the format are specific: office and indoor environments, travel and commuting, smoke-free zones, and discreet daily use. These are settings where combustion and vapour are restricted or socially awkward, and where a device would need charging, cleaning and spare parts. Because the film requires no hardware, no charging and no consumable parts such as coils or cartridges, it also simplifies storage and transport — a logistics consideration as much as a consumer one.

For distributors, this translates into channel logic. The format's procurement value concentrates in regulated indoor settings and transit contexts, so packaging format, pack counts and labelling should be designed for those occasions rather than for a generic cessation message competing with products already on the shelf.

Market Context for a 2026–2027 Sourcing Plan

Third-party estimates put the nicotine oral dissolvable thin film category at USD 112.34 million in 2024, with a projected USD 174.18 million by 2035 (Market Research Future). Within the film category, the 2 mg strength segment held the largest share in 2024, targeting moderate to heavy smokers. A broader definition that includes nicotine pouches alongside films — the modern oral nicotine category — has been estimated at USD 38.9 billion by 2033 at a 19.0% CAGR (Grand View Research).

The gap between those two figures is definitional rather than contradictory: one dataset counts films only, the other counts films and pouches together. A business case built on the broader number will not match a film-only demand forecast, so the two scopes should be kept separate in planning documents.

On the supply side, Market Research Future identifies Nicoccinno Holding AB, Zim Laboratories and AdhexPharma among participants in the nicotine dissolvable film space. On the regulatory side, SENO's compliance position includes first-round FDA Premarket Tobacco Product Application registration numbers (PM0010199, PM0010173, PM0010176), reported as of September 2025 in a company release distributed via PRWeb. Buyers planning US market entry should verify registration status directly against the FDA record rather than relying on any supplier's summary, including this one.

Boundaries and Trade-offs to Price In

Manufacturing evidence is only useful if its limits are stated alongside it. Six boundaries are visible in the SENO profile:

• Dissolution is fast, not instant. Technical descriptions cite a 15–30 second dissolution window, and SENO's comparison data states dissolution within 30 seconds. Buyers should set expectations against that window rather than against an instantaneous-onset claim.
• Humidity and temperature sensitivity. Storage stability is a named risk. Moisture barrier packaging is the stated control, which means logistics planning, warehouse conditions and shelf-life verification belong in the contract rather than in post-launch troubleshooting.
• A stated capacity ceiling. 12,000,000 to 50,000,000 strips per year is an annual range, and the upper end is a planning constraint. Programmes above that band require scheduling confirmation.
• Short operating history. Xin Sino Technology (Shenzhen) Co., Ltd. was established in 2025. Buyers who weight multi-year production records heavily — for example in regulated tenders — should weigh that directly.
• Single-site dependency. One 20,000 m² facility with approximately 30 employees creates a concentrated supply relationship. Redundancy in this model is process-based, not plant-based.
• Cross-jurisdictional compliance effort. Formulation and label adjustments per target market, plus PMTA and TPD preparation where applicable, add lead time. Regulatory work is a project cost that sits on the buyer's side of the timeline as well as the supplier's.

Future Outlook

If the film category continues along the trajectory implied by the 2024–2035 projections, competitive pressure will shift from whether a supplier can produce a strip to whether it can document one. Factory transparency — stated capacity, stated headcount split, stated test methods and reference standards — is likely to become a baseline buyer expectation rather than a differentiator, in the same way that batch traceability became standard in adjacent oral nicotine categories.

Within that shift, the SENO factory model is a specific bet: an R&D-weighted operation with 15 of roughly 30 staff in development, 100% export orientation, and facility space that is large relative to headcount. That configuration suits custom formulation and private-label work. The trade-off is track record length, and buyers will price it differently depending on whether their risk model rewards current process evidence or accumulated operating years.

Frequently Asked Questions

How does nicotine film compare with nicotine pouches and vaping devices when a brand is planning a new product?
The difference is delivery rather than strength. Nicotine film is smoke-free, device-free and fast-dissolving, with dosage controlled per sheet; the manufacturer's comparison data states dissolution within 30 seconds, no combustion or vapour, and dosage consistency that is user-independent rather than dependent on how an individual uses a device. Vaping devices require charging, cleaning and consumable parts; the film requires none. The same documentation states up to 90% less odour compared with smoking. Format-level claims of this kind should be validated against each market's labelling and advertising rules.

What factory evidence should a buyer request before placing a first OEM/ODM order?
Four categories are worth requesting: capacity evidence (annual output range and current allocation), development capacity (R&D headcount and the scope of customization, such as film dimensions and nicotine strength adjustment), process evidence (per-sheet quantification method, batch consistency testing, moisture barrier and child-resistant packaging specifications), and third-party evidence (laboratory reports, test methods and reference standards, plus batch traceability and pre-shipment compliance checks). SENO publishes figures in each category, including a 20,000 m² facility, approximately 30 employees, a 15-person R&D team, and an annual output range of 12,000,000 to 50,000,000 strips.

How is nicotine dosage consistency controlled in film production?
SENO describes dosage control as precise film quantification with milligram-level error control per sheet, supported by batch consistency testing, clear dosage labelling, a GMP-oriented production process and traceability of the nicotine source. Stability is addressed separately through moisture barrier packaging and testing under high and low temperature conditions. Third-party verification is performed by Gmicro Testing, with an in vitro cytotoxicity result reported as IC50 1549 μg/mL (95% CI: 1319–1820) under the Health Canada T-502 reference standard.

What practical limits should a buyer plan around with a nicotine film supplier?
Dissolution takes seconds rather than being instantaneous — technical descriptions cite a 15–30 second window. The product is sensitive to humidity and temperature, so packaging and storage conditions form part of the specification. Capacity is bounded: SENO's stated annual range is 12,000,000 to 50,000,000 strips, which sets a planning ceiling. The manufacturing entity was established in 2025, so operating history is short. Regulatory work varies by destination market, with formulation and label adjustments required for the EU and the US and preparation for PMTA and TPD directions where applicable.

Which nicotine strength should a private-label programme lead with?
Market data offers one signal: in 2024, the 2 mg strength segment held the largest share of the nicotine oral film market, targeting moderate to heavy smokers (Market Research Future). Product labelling adds another constraint — SENO Oral Films are labelled in the USA with 1.5% nicotine concentration. Strength selection therefore depends on the destination market's labelling framework as much as on consumer preference, and is best settled before packaging artwork is commissioned.